Nephrology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the 49th Annual Meeting of the European Association for the Study of the Liver (EASL)

New Direct-acting Antiviral Agents in the Treatment of Hepatitis C Genotype 1 Infection

London, UK / April 9-13, 2014

Guest Editor: Jordan J. Feld, MD, MPHToronto Centre for Liver DiseaseToronto Western HospitalFrancis Family Liver ClinicUniversity Health NetworkMcLauglin-Rotman Centre for Global HealthToronto,...

PRIORITY PRESS - Kidney Week - American Society of Nephrology (ASN)

Expanding Therapeutic Tools Encourage Individualized Therapy for ANCA Vasculitis

Atlanta, Georgia / November 5-10, 2013

Atlanta - A treatment algorithm is evolving for anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis based on disease severity. Although the therapeutic options remain limited, they have expanded, permitting treatment to be...

PRIORITY PRESS - Kidney Week - American Society of Nephrology (ASN)

Unpredictability of aHUS and Benefit of Early Therapy Supports High Index of Suspicion

Atlanta, Georgia / November 5-10, 2013

Atlanta - Atypical hemolytic uremic syndrome (aHUS) affects both children and adults, is characterized by systemic thrombotic microangiopathy, which can lead to stroke, heart attack, kidney failure, and death. Despite plasma...

PRIORITY PRESS - Annual General Meeting of the Canadian Society of Nephrology

Exploring B-cell Targeted Therapy in the Management of Glomerulonephritis

Montreal, Québec / April 24-28, 2013

Montreal - Treatment of glomerulonephritis has long been dependent on the use of steroids plus cytotoxic or antiproliferative drugs. With the success of therapeutic monoclonal agents in other autoimmune diseases, their use in...

MEDICAL FRONTIERS - 48th Annual Meeting of the European Association for the Study of the Liver

New Protease Inhibitor Data Support Large Leap in Hepatitis C Virus Control

Amsterdam, The Netherlands / April 24-28, 2013

Amsterdam - In the rapidly evolving field of hepatitis C virus (HCV), protease inhibitors (PIs) are poised to provide additional incremental increases to sustained virologic remission (SVR) rates in difficult cases. Since their...

PRIORITY PRESS - Annual General Meeting of the Canadian Society of Nephrology

New Insights in the Treatment of Atypical Hemolytic Uremic Syndrome

Montreal, Quebec / April 24-28, 2013

Montreal - Atypical hemolytic uremic syndrome (aHUS) is a rare condition caused by a genetic or acquired deficiency in the complement system. Its features include progressive and potentially fatal involvement of the kidneys and circulatory...

PRIORITY PRESS - Annual General Meeting of the Canadian Society of Nephrology

Type 2 Diabetes and Antihyperglycemics: A View from the Kidney

Montreal, Québec / April 24-28, 2013

Montreal - A new class of antihyperglycemic agents, the sodium-glucose co-transporter 2 inhibitors significantly reduce both blood pressure and weight beyond achieving glucose-lowering effects through an insulin-independent mechanism. As...

PRIORITY PRESS - 2012 Kidney Week of the American Society of Nephrology (ASN)

Options for Iron Correction and Erythropoiesis Stimulation: Better Benefit:Risk Through Individualized Therapy

San Diego, California / October 30 - November 4, 2012

San Diego - More sophisticated strategies for the treatment of anemia in patients with chronic kidney disease (CKD), including those on dialysis, are being driven by new options for replenishing iron and stimulating erythropoiesis. The...

PRIORITY PRESS - 2012 Kidney Week of the American Society of Nephrology (ASN)

Halting Threat of Kidney Failure by Hemolytic Uremic Syndrome and Other Thrombotic Microangiopathies

San Diego, California / October 30-November 4, 2012

San Diego - Two-year results with a targeted monoclonal antibody (MAb) against the complement protein C5 demonstrated that the kidney damage caused by atypical hemolytic uremic syndrome (aHUS) and shiga-toxin producing Escherichia coli HUS...

ABSTRACTS in PERSPECTIVE - Based on presentations from the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Weighing Benefits of SGLT2 Inhibition in Type 2 Diabetes Mellitus

Berlin, Germany / October 1-5, 2012

EDITORIAL OVERVIEW: David C. W. Lau, MD, PhD, FRCPCEditor-in-Chief, Canadian Journal of DiabetesProfessor of Medicine, Biochemistry & Molecular BiologyJulia McFarlane Diabetes Research CentreUniversity of CalgaryCalgary, AlbertaRonald...

PAGE 1 OF 6   1 2 3 4 5 6